Société de sciences de la vie Collaborations
Accelerating Company Growth: viDATherapeutics
The Centre for Drug Research and Development (CDRD) AND and viDA Therapeutics Inc. (viDA) a privately-held biotech company have been working together to develop viDA’s patented lead drug candidate, VTI-1002, advance it to a commercial stage, and in doing so, position the company for further private sector investment and/or strategic partnership.
CDRD’s Vice President of Scientific Operations, Dr. Jason Crawford commented, “Our partnership with viDA Therapeutics has demonstrated that collaboration is paramount to commercializing new therapies, and is a great example of how CDRD can support not only academic scientists, but also small-and medium-sized Canadian enterprises. By bringing our expertise and specialized infrastructure to bear, we have helped enable the building of a strong local biotech company, and ultimately broader industry –all while bringing new hope to patients.”
viDA’s President and CEO, Alistair Duncan added, “There is an immediate unmet clinical need to develop an effective therapy. Working with CDRD has helped to accelerate the development of our technology in addition to generating additional funding from industry. This has allowed us to hire more staff and investigate other uses beyond DLE –essentially building viDA’s core value and strategic positioning.”
CDRD is now working with viDA on target validation studies for GzmB in other autoimmune diseases.